BRIEF published on 12/23/2024 at 21:09, 1 year 3 months ago Succès de l'offre publique de TME Pharma N.V. Actionnaires Augmentation De Capital Cancer NOX-A12 Stratégies Financières
BRIEF published on 12/23/2024 at 21:09, 1 year 3 months ago Successful public offering of TME Pharma NV Shareholders Capital Increase Cancer Financial Strategies NOX-A12
PRESS RELEASE published on 12/23/2024 at 21:04, 1 year 3 months ago Informations privilégiées / Autres communiqués TME Pharma réussit son offre publique de 2,6 millions d'euros, renforçant sa position financière jusqu'en juin 2025. Les actionnaires soutiennent la levée de fonds pour NOX-A12 et NOX-E36 Augmentation De Capital Offre Publique TME Pharma NOX-A12 NOX-E36
BRIEF published on 12/04/2024 at 19:55, 1 year 3 months ago TME Pharma annonce une mise à jour stratégique et un plan de financement de 2,6 millions d'euros Stratégie D'entreprise Offre Publique Plan De Financement Développement Du NOX-A12 Priorité Aux Actionnaires
BRIEF published on 12/04/2024 at 19:55, 1 year 3 months ago TME Pharma Announces Strategic Update and €2.6 Million Financing Plan Public Offer Corporate Strategy Financing Plan NOX-A12 Development Shareholder Priority
PRESS RELEASE published on 12/04/2024 at 19:50, 1 year 3 months ago Informations privilégiées / Autres communiqués TME Pharma annonce une nouvelle stratégie et un financement garanti de 2,6 millions d'euros pour ses projets NOX-A12 et NOX-E36 jusqu'en juin 2025 Financement Offre Publique TME Pharma NOX-A12 NOX-E36
PRESS RELEASE published on 12/04/2024 at 19:50, 1 year 3 months ago Inside Information / Other news releases TME Pharma announces corporate strategy update with upcoming €2.6 million financing aimed at further developing therapies for cancer treatment through public offer open to shareholders. CEO Mangasarian highlights strategic goals and plans Financing Cancer Treatment Public Offer Corporate Strategy TME Pharma
BRIEF published on 11/23/2024 at 10:59, 1 year 4 months ago TME Pharma présente ses résultats sur NOX-A12 dans le glioblastome Thérapie Contre Le Cancer Glioblastome NOX-A12 Inhibition Du Point De Contrôle Immunitaire Microenvironnement Tumoral
BRIEF published on 11/23/2024 at 10:59, 1 year 4 months ago TME Pharma Presents Findings on NOX-A12 in Glioblastoma Cancer Therapy Glioblastoma NOX-A12 Immune Checkpoint Inhibition Tumor Microenvironment
PRESS RELEASE published on 11/23/2024 at 10:54, 1 year 4 months ago Informations privilégiées / Autres communiqués TME Pharma annonce la présentation d'un poster par le National Cancer Institute américain sur l'inhibition de CXCL12 par NOX-A12 dans le glioblastome à la réunion annuelle du SNO 2024 Glioblastome TME Pharma NOX-A12 National Cancer Institute Inhibition
Published on 03/27/2026 at 09:30, 1 hour 10 minutes ago Amap Street Stars Launches Macao Authentic Delicacies Ranking to Drive Cultural-Tourism Innovation in the Greater Bay Area
Published on 03/27/2026 at 08:05, 2 hours 35 minutes ago Battery X Metals Announces Corporate Awareness Engagements
Published on 03/26/2026 at 23:00, 11 hours 40 minutes ago FutureGen Industries Announces Closing of Debt Settlement
Published on 03/26/2026 at 22:05, 12 hours 35 minutes ago BlackBerry to Announce Fourth Quarter and Fiscal Year 2026 Results on April 9, 2026
Published on 03/26/2026 at 22:00, 12 hours 40 minutes ago Clean Air Metals Receives Provincial Funding and Provides Update on the Thunder Bay North Project
Published on 03/27/2026 at 10:23, 17 minutes ago Original-Research: HORNBACH Holding AG & Co. KGaA (von Quirin Privatbank Kapitalmarktgeschäft): Buy
Published on 03/27/2026 at 10:00, 40 minutes ago AlphaPet Ventures welcomes Cpro Food, one of the leading super-premium brands for dog and cat food in Belgium
Published on 03/27/2026 at 09:45, 55 minutes ago DESTINUS Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026
Published on 03/27/2026 at 09:39, 1 hour ago Grünenthal achieves outstanding financial results in 2025, powered by strategic growth, integration and diversification
Published on 03/27/2026 at 09:37, 1 hour 3 minutes ago MEDICLIN lays a solid foundation for further growth with its 2025 financial results
Published on 03/27/2026 at 07:00, 3 hours 40 minutes ago WEB SA - CONVOCATION ASSEMBLEE GENERALE ORDINAIRE EXERCICE 2025 - 28/04/2026
Published on 03/26/2026 at 18:17, 16 hours 23 minutes ago Eiffage se renforce au capital de Getlink et porte sa participation à 29,40 % du capital
Published on 03/26/2026 at 18:17, 16 hours 23 minutes ago Eiffage strengthens its position in Getlink capital
Published on 03/26/2026 at 18:00, 16 hours 40 minutes ago Arrêté des comptes au 31 décembre 2025 et perspectives 2026
